SWTX News

News
all
press releases
More News
After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.
Stocktwits
Investing.com -- Shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.
investing.com
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Stocktwits
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
Stocktwits
Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.
Stocktwits
Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.
Stocktwits
Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s Merck (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.
investing.com

Advertisement|Remove ads.